{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/ASND/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-15T15:46:46.724Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":3957,"canonical_name":"Ascendis Pharma A/S","cik":"0001612042","uei":null,"lei":null,"duns":null,"ticker":"ASND"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":33,"clinical":2},"count":35,"timeline":[{"ts":"2026-10-14","kind":"sec.filing","form_type":"6-K","title":"6-K — Ascendis Pharma A/S — 2026-10-14","url_slug":"/sec/cik-0001612042/6-k/0001193125-26-421789","accession_number":"0001193125-26-421789","importance":30},{"ts":"2026-09-29","kind":"sec.filing","form_type":"6-K","title":"6-K — Ascendis Pharma A/S — 2026-09-29","url_slug":"/sec/cik-0001612042/6-k/0001193125-26-407293","accession_number":"0001193125-26-407293","importance":30},{"ts":"2026-09-15","kind":"sec.filing","form_type":"6-K","title":"6-K — Ascendis Pharma A/S — 2026-09-15","url_slug":"/sec/cik-0001612042/6-k/0001193125-26-390874","accession_number":"0001193125-26-390874","importance":30},{"ts":"2026-09-15","kind":"sec.filing","form_type":"6-K","title":"6-K — Ascendis Pharma A/S — 2026-09-15","url_slug":"/sec/cik-0001612042/6-k/0001193125-26-390877","accession_number":"0001193125-26-390877","importance":30},{"ts":"2026-09-09","kind":"sec.filing","form_type":"4","title":"4 — Ascendis Pharma A/S — 2026-09-09","url_slug":"/sec/cik-0001612042/4/0001610717-26-000409","accession_number":"0001610717-26-000409","importance":30},{"ts":"2026-09-09","kind":"sec.filing","form_type":"6-K","title":"6-K — Ascendis Pharma A/S — 2026-09-09","url_slug":"/sec/cik-0001612042/6-k/0001193125-26-386434","accession_number":"0001193125-26-386434","importance":30},{"ts":"2026-09-09","kind":"sec.filing","form_type":"6-K","title":"6-K — Ascendis Pharma A/S — 2026-09-09","url_slug":"/sec/cik-0001612042/6-k/0001193125-26-386630","accession_number":"0001193125-26-386630","importance":30},{"ts":"2026-09-08","kind":"sec.filing","form_type":"144","title":"144 — Ascendis Pharma A/S — 2026-09-08","url_slug":"/sec/cik-0001612042/144/0001964306-26-000432","accession_number":"0001964306-26-000432","importance":30},{"ts":"2026-09-03","kind":"sec.filing","form_type":"4","title":"4 — Ascendis Pharma A/S — 2026-09-03","url_slug":"/sec/cik-0001612042/4/0001610717-26-000395","accession_number":"0001610717-26-000395","importance":30},{"ts":"2026-09-02","kind":"sec.filing","form_type":"144","title":"144 — Ascendis Pharma A/S — 2026-09-02","url_slug":"/sec/cik-0001612042/144/0001973379-26-000330","accession_number":"0001973379-26-000330","importance":30},{"ts":"2026-08-31","kind":"sec.filing","form_type":"6-K","title":"6-K — Ascendis Pharma A/S — 2026-08-31","url_slug":"/sec/cik-0001612042/6-k/0001193125-26-376733","accession_number":"0001193125-26-376733","importance":30},{"ts":"2026-08-13","kind":"sec.filing","form_type":"6-K","title":"6-K — Ascendis Pharma A/S — 2026-08-13","url_slug":"/sec/cik-0001612042/6-k/0001193125-26-348046","accession_number":"0001193125-26-348046","importance":30},{"ts":"2026-08-13","kind":"sec.filing","form_type":"6-K","title":"6-K — Ascendis Pharma A/S — 2026-08-13","url_slug":"/sec/cik-0001612042/6-k/0001612042-26-000016","accession_number":"0001612042-26-000016","importance":30},{"ts":"2026-08-12","kind":"sec.filing","form_type":"6-K","title":"6-K — Ascendis Pharma A/S — 2026-08-12","url_slug":"/sec/cik-0001612042/6-k/0001193125-26-347172","accession_number":"0001193125-26-347172","importance":30},{"ts":"2026-08-06","kind":"sec.filing","form_type":"6-K","title":"6-K — Ascendis Pharma A/S — 2026-08-06","url_slug":"/sec/cik-0001612042/6-k/0001193125-26-337270","accession_number":"0001193125-26-337270","importance":30},{"ts":"2026-07-28","kind":"clinical.trial","reporter":"Ascendis Pharma A/S","title":"A Study to Test the Effects and Safety of Palopegteriparatide in Adolescents With Long-term Hypoparathyroidism","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07706764","excerpt":"[\"Hypoparathyroidism\"]","importance":60},{"ts":"2026-07-15","kind":"sec.filing","form_type":"6-K","title":"6-K — Ascendis Pharma A/S — 2026-07-15","url_slug":"/sec/cik-0001612042/6-k/0001193125-26-304903","accession_number":"0001193125-26-304903","importance":30},{"ts":"2026-06-30","kind":"sec.filing","form_type":"6-K","title":"6-K — Ascendis Pharma A/S — 2026-06-30","url_slug":"/sec/cik-0001612042/6-k/0001193125-26-290485","accession_number":"0001193125-26-290485","importance":30},{"ts":"2026-06-29","kind":"sec.filing","form_type":"6-K","title":"6-K — Ascendis Pharma A/S — 2026-06-29","url_slug":"/sec/cik-0001612042/6-k/0001193125-26-288414","accession_number":"0001193125-26-288414","importance":30},{"ts":"2026-06-17","kind":"sec.filing","form_type":"6-K","title":"6-K — Ascendis Pharma A/S — 2026-06-17","url_slug":"/sec/cik-0001612042/6-k/0001193125-26-274306","accession_number":"0001193125-26-274306","importance":30},{"ts":"2026-06-15","kind":"sec.filing","form_type":"6-K","title":"6-K — Ascendis Pharma A/S — 2026-06-15","url_slug":"/sec/cik-0001612042/6-k/0001193125-26-270227","accession_number":"0001193125-26-270227","importance":30},{"ts":"2026-06-12","kind":"sec.filing","form_type":"6-K","title":"6-K — Ascendis Pharma A/S — 2026-06-12","url_slug":"/sec/cik-0001612042/6-k/0001193125-26-268415","accession_number":"0001193125-26-268415","importance":30},{"ts":"2026-06-10","kind":"sec.filing","form_type":"6-K","title":"6-K — Ascendis Pharma A/S — 2026-06-10","url_slug":"/sec/cik-0001612042/6-k/0001193125-26-265829","accession_number":"0001193125-26-265829","importance":30},{"ts":"2026-06-02","kind":"sec.insider.p","reporter":"SMITH SCOTT THOMAS","title":"EVP & Chief Financial Officer","shares":100,"price_per_share":219,"usd_value":21900,"security_title":"Ordinary Shares","importance":50.0219},{"ts":"2026-06-02","kind":"sec.filing","form_type":"4","title":"4 — Ascendis Pharma A/S — 2026-06-02","url_slug":"/sec/cik-0001612042/4/0001610717-26-000179","accession_number":"0001610717-26-000179","importance":30},{"ts":"2026-06-01","kind":"sec.filing","form_type":"3/A","title":"3/A — Ascendis Pharma A/S — 2026-06-01","url_slug":"/sec/cik-0001612042/3-a/0001610717-26-000175","accession_number":"0001610717-26-000175","importance":30},{"ts":"2026-06-01","kind":"sec.filing","form_type":"4","title":"4 — Ascendis Pharma A/S — 2026-06-01","url_slug":"/sec/cik-0001612042/4/0001610717-26-000176","accession_number":"0001610717-26-000176","importance":30},{"ts":"2026-05-29","kind":"sec.insider.p","reporter":"SMITH SCOTT THOMAS","title":"EVP & Chief Financial Officer","shares":250,"price_per_share":223.32,"usd_value":55830,"security_title":"Ordinary Shares","importance":50.05583},{"ts":"2026-05-29","kind":"sec.insider.p","reporter":"BIENAIME JEAN JACQUES","title":null,"shares":200,"price_per_share":223.76,"usd_value":44752,"security_title":"Ordinary Shares","importance":50.044752},{"ts":"2026-05-29","kind":"sec.insider.p","reporter":"BIENAIME JEAN JACQUES","title":null,"shares":200,"price_per_share":222.3,"usd_value":44460,"security_title":"Ordinary Shares","importance":50.04446},{"ts":"2026-05-29","kind":"sec.insider.p","reporter":"BIENAIME JEAN JACQUES","title":null,"shares":100,"price_per_share":223.5,"usd_value":22350,"security_title":"Ordinary Shares","importance":50.02235},{"ts":"2026-05-13","kind":"sec.filing","form_type":"6-K","title":"6-K — Ascendis Pharma A/S — 2026-05-13","url_slug":"/sec/cik-0001612042/6-k/0001193125-26-221597","accession_number":"0001193125-26-221597","importance":30},{"ts":"2026-05-12","kind":"sec.filing","form_type":"4","title":"4 — Ascendis Pharma A/S — 2026-05-12","url_slug":"/sec/cik-0001612042/4/0001610717-26-000159","accession_number":"0001610717-26-000159","importance":30},{"ts":"2026-05-11","kind":"sec.insider.s","reporter":"JENSEN FLEMMING STEEN","title":"See Remarks","shares":19460,"price_per_share":238.4903,"usd_value":4641021,"security_title":"Ordinary Shares","importance":39.641021238},{"ts":"2026-04-21","kind":"clinical.trial","reporter":"Ascendis Pharma A/S","title":"A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia.","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT06732895","excerpt":"[\"Achondroplasia\"]","importance":45}]}